Parabilis Medicines secures $305 million in Series F funding led by RA Capital Management to advance FOG-001 clinical development and support its innovative Helicon platform.
Amount Raised
$305 Million
Round Type
Series F
CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Parabilis Medicines announced the closing of an oversubscribed $305 million Series F financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors. The funding will support the clinical development of FOG-001 (zolucatetide) and advance the company's pioneering pipeline. Strong participation from existing and new investors highlights confidence in Parabilis' innovative approach to cancer treatment. The financing closed at an increased valuation compared to prior funding rounds.
Quick answer
Parabilis Medicines raised $305 Million in a Series F round, dated January 8, 2026. Investors: Rock Springs Capital, Alderline Group, venBio Partners, T. Rowe Price Associates, Inc., Samsara Biocapital, Hbm Healthcare, ARCH Venture Partners and RA Capital Management. Parabilis Medicines is based in Cambridge, Massachusetts, United States.
- How much did Parabilis Medicines raise?
- Parabilis Medicines raised $305 Million in a Series F round on January 8, 2026.
- Who invested in Parabilis Medicines?
- Rock Springs Capital, Alderline Group, venBio Partners, T. Rowe Price Associates, Inc., Samsara Biocapital, Hbm Healthcare, ARCH Venture Partners and RA Capital Management are named as investors in this round.
- What does Parabilis Medicines do?
- Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer.
- Where is Parabilis Medicines based and how big is it?
- Parabilis Medicines is based in Cambridge, Massachusetts, United States. Fundz records about 170 employees.
- Who are the decision-makers at Parabilis Medicines?
- Fundz holds 1 contact at Parabilis Medicines, including the Chairman, CEO and President. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Parabilis Medicines that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $3.5M on January 14, 2026.
- CASI Pharmaceuticals raised $5M on December 27, 2025.
- Terns Pharmaceuticals raised $196M (Post-IPO Equity) on December 11, 2025.
- Citius Oncology raised $18M (Funding Round) on December 9, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.3M on November 28, 2025.
- Korsana Biosciences raised $175M (Series A) on February 18, 2026.
Who to call at Parabilis Medicines, and when
A new round usually means Parabilis Medicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Parabilis Medicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Parabilis Medicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Parabilis Medicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Parabilis Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Parabilis Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.